Search

In the article, the author discusses how rehabilitation (rehab) speech-language pathologists (SLP) can help their patients under skilled maintenance therapy to receive Medicare reimbursements in the U.S. Other topics include the key role of rehab SLPs in helping patients improve their speech and communication skills, and the differences between rehabilitative/restorative therapy and maintenance programs under Medicare.

The article discusses a study which reported that decreased cone density was a characteristic in patients with multiple sclerosis (MS) evaluated by investigators in the United Kingdom. Topics include main outcome measures of the study, significant thinning of the inner retina and thickening of the outer retina in eyes with a history of optic neuritis, and differences seen in the peripapillary retinal nerve fiber layer.

Ion mobility mass spectrometry (IMMS) is a two-dimensional technique that allows separation of ionized molecules based on molecular size, shape, and mass-to-charge ratio (m/z). It has rapidly become a valuable application for analyzing isomeric compounds in a complex matrix (for example, proteomic and llipidomic samples) or complex mixtures of structurally related and isobaric analytes (such as oil samples or polymer blends). IMMS was investigated as a possible technique to compare purported generic products with Copaxone (glatiramer acetate), a drug for treating relapsing-remitting multiple sclerosis that contains a very complex mixture of synthetic peptides. The analysis was performed on 15 randomly chosen batches of Copaxone and five batches of purported generics that are marketed drugs in their country of origin. [ABSTRACT FROM AUTHOR]

The article describes an activity program for continuing education which teaches concepts related to treatment of multiple sclerosis (MS) including factors for drug therapy selection, available treatment, and the role of pharmacists for MS management.

The National Institute for Health and Care Excellence (NICE) has updated its guideline for management of patients with multiple sclerosis (MS). It offers fresh recommendations for diagnosis, support, care coordination and symptom management, in line with advances. MS specialist nurse Nicola Daykin says: 'There are now 18 treatments. When I started in 2008, there were three. There's more choice for patients and clinical professionals so the guidelines need to reflect that.' [ABSTRACT FROM AUTHOR]

The article discusses treatment regimens available for multiple sclerosis. Topics mentioned include a brief description of the neurologic disorder, factors that can contribute to the development of multiple sclerosis including environment, age, and geography, and prevention of relapses and disease progression as the treatment goals for patients with the disease with the use of disease-modifying drugs.

This article describes the complex neurological condition multiple sclerosis (MS) and its management. It outlines the pathophysiology and symptoms, the importance of timely access to specialist services for treatment of symptoms, and relapse and disease management. New and emerging therapies for the management of MS, the role of the multidisciplinary team, the importance of holistic assessment and the role of the MS specialist nurse are discussed. Self-management of MS is integral to managing this life-limiting long-term condition. While there is no cure for MS, new and oral disease-modifying therapies providing better efficacy in stabilising the disease have recently been introduced, reducing relapse frequency and disease activity, and delaying the progression of disability. [ABSTRACT FROM AUTHOR]

The article reviews several drugs including the Sovaldi (sofosbuvir) for treating hepatitis C developed by Gilead, the Tecfidera (Dimethyl Fumarate) for treating multiple sclerosis from Biogen Idec, and Otezla (Apremilast) for treating Psoriatic Arthritis from Celgene.

The article presents guidelines for a pharmacist-focused approach to improving outcomes in patient with multiple sclerosis (MS). Therapy goals for MS include controlling symptoms, preventing the progression of the disease, improving function and reducing long-term disability. A short course of high dosage corticosteroids are commonly given to manage acute symptomatic exacerbations of MS. Other drugs for MS treatment include mitoxantrone, natalizumab and oral therapies.

The article discusses about the Optic neuritis is an inflammation of the optic nerve that often occurs in association with multiple sclerosis (MS) and the use of Magnetic resonance imaging (MRI) is highly sensitive for and specific in the assessment of inflammatory changes in the optic nerves. The article also mentions some drugs including interferon beta-1b, interferon beta-1a, and glatiramer acetate for the treatment of multiple sclerosis.

The article discusses diagnosis and treatment of optic neuritis and multiple sclerosis (MS). Topics include magnetic resonance imaging (MRI), clinically definite mul­tiple sclerosis (CDMS) and neurological impairment. Drugs including Betaseron, Rebif and Copaxone are mentioned. Clinical studies on the treatment are also discussed.

The article presents a case study on the commercialization of 4-aminopyridine, a drug developed by the researchers at Rush University Medical Center in Chicago, Illinois as a treatment for multiple sclerosis (MS). The drug has finally been approved by the U.S. Food and Drug Administration (FDA) in January 2010 under the name Ampyra. The large biotech firm Regis Technologies was the sole supplier of the active pharmaceutical ingredient (API), which will possibly increase the sales of Ampyra.

Reports on the development of drugs capable of slowing down the progression of multiple sclerosis (MS). Emergence of relationship between optic neuritis and multiple sclerosis; Characterization of MS by neurologic dysfunction disseminated in time and space; United States Food & Drug Administration's approval of three immunomodulatory drugs reducing MS attacks.

Reports on a cooling technology being offered by the National Aeronautics and Space Administration (NASA) derived from its extravehicular activity suit to help victims of multiple sclerosis (MS). Effect of a one degree Fahrenheit decrease in core body temperature on MS victims; NASA's program sharing with the Multiple Sclerosis Association.

The article offers news briefs on special medications as of September 1, 2016. Topics include the approval of several specialty medications by the U.S. Food and Drug Administration (FDA) like Zepatier (elbasvir/grazoprevir) from Merck & Co. Inc. for treatment of hepatitis C, the Ocrevus biologic drug from Genentech for treatment of relapsing multiple sclerosis (MS), and the olaratumab, a breakthrough therapy from Eli Lilly for treatment of patients with advanced soft tissue sarcoma (STS).

The article focuses on the funding made by the pharmaceutical company Roche to drug developing company Inception 5, for a multiple sclerosis drug program.

The article reports on the plan of U.S. biotechnology company Biogen to take over the development of ALKS 8700, an Alkermes small-molecule drug for multiple sclerosis (MS) which is in Phase III clinical trials and will compete with Biogen's MS drug Tecfidera.

The article presents questions and answers related to proper herbal supplements for disease treatment and prevention like ginkgo supplements for multiple sclerosis treatment, a herbal solution for treating hepatitis C virus, and dehydroepiandrosterone for treating infertility.

The article reports on the side-effect issues associated with drugs used for the treatment of multiple sclerosis (MS), which include Novartis' Gilenya, Biogen Idec, and Elan's Tysabri.

In the face of cuts, MS nurse specialists are having to prove their worth, as Lynne Wallis reports. [ABSTRACT FROM AUTHOR]

Advances in knowledge about multiple sclerosis could lead to earlier diagnosis and treatment, as Catherine Quinn reports. [ABSTRACT FROM AUTHOR]

This section offers news briefs relating to the field of nursing in Great Britain as of September 14, 2016, including an item about a research published by charity Multiple Sclerosis (MS) Trust, an item about projects for improving men's health, and an item about young people with eating disorders.

A calendar of nursing events in Great Britain from September-October 2016 is presented, including "European Committee for Treatment and Research in Multiple Sclerosis" congress, "British Institute of Learning Disabilities Annual Conference," and "The Future of Healthcare Services in Wales" seminar.

The MS Trust is refusing to endorse guidance from the National Institute for Health and Care Excellence because the advice fails to mention nurse specialists. [ABSTRACT FROM AUTHOR]

The article explores the treatment of multiple sclerosis (MS). MS refers to an idiopathic central nervous system (CNS) inflammatory autoimmune disease causing the demyelination of nerve fibers. Among the four subtypes that are used to classify the condition include relapsing-remitting MS and primary progressive MS. Research shows that glucocorticosteroids are capable of shortening the relapse duration, but seem to have little effect on changing disease progression. Physical and occupational therapy and pharmacotherapy focus on secondary symptoms.

The article provides information on various multiple sclerosis (MS) treatments in the U.S. It includes primary disease-modifying therapies such as Avonex, Betaseron and Copazone. Meanwhile, several other monoclonal antibody medications are in clinical trials as of 2008 including Alemtuzumab, Rituxmab and Fingolimod.

Provides information on a study which examined the effectiveness of the use of methylprednisolone and oral prednisone drugs on optic neuritis patients. Information on clinical trials using the medications for optic neuritis and placebo drugs; Implication of the results of the study on the use of magnetic resonance brain imaging in multiple sclerosis patients; Methodology and discussion.

The article focuses on research published in the journal "Nature Neuroscience" in 2015 in which researchers Jeffery D. Haines and Patrizia Casaccia, and their team showed that inhibiting a transporter protein can relieve multiple-sclerosis like symptoms in mice, a possible new treatment strategy.

The article mentions that the U.S. high court Justice Stephen G. Breyer ordered in favor of Teva Pharmaceutical Industries Ltd. in the court case regarding disputed patents of multiple sclerosis drug Copaxone, that expired in September 2014.

The article reports that French pharmaceutical firm Servier is planning to pay 47 million dollars to Geneva-based GeNeuro as an option to license drug GNbACi, a treatment to the cause of multiple sclerosis in Phase II studies.

Reports on the Optic Neuritis Treatment Trial that has spawned a new study that proposes to determine whether recombinant human interferon beta-1a can delay the onset of clinically definite multiple sclerosis (MS). Determination of high risk for MS based on multiple magnetic resonance imaging signal abnormalities in the brain; Initial treatment; Eligibility; Prediction of MS.

Reports on the approval of the Food and Drug Administration (FDA) on the marketing of beta-interferon to treat multiple sclerosis. Development by Chiron and Schering A.G.; Benefit for ambulatory patients suffering from the relapsing-remitting form of the disease; FDA's accelerated approval regulations; Adverse effects.

NeuroResponse is a nurse-led service for people with multiple sclerosis (MS) and long-term neurological conditions. [ABSTRACT FROM AUTHOR]

Debbie Quinn hails the progress made in multiple sclerosis care, but says more needs to be done. [ABSTRACT FROM AUTHOR]

Lynne Pearce talks to a nurse of the year who made a huge difference to multiple sclerosis patients. [ABSTRACT FROM AUTHOR]

The article offers information on Tecfidera, an oral fumaric acid derivative developed by Biogen Idec, and approved for the treatment of relapsing forms of multiple sclerosis.

The article describes prescription products approved by the U.S. Food and Drug Administration (FDA) including Tecfidera capsules for multiple sclerosis from Biogen Idec, Iclusig tablets for myeloid leukemia from Ariad Pharmaceuticals, and Flublok influenza vaccine from Protein Sciences Corp.

The article reports that Opexa Therapeutics Inc. has done an agreement with pharmaceutical companies Tcelna and Merck Serono SA for developing the t-cell immunotherapy for multiple sclerosis and informs that the therapy is under phase-II clinical trials.

The article reports that the drug development company Biogen Idec Inc. will procure the multiple sclerosis treatment Tysabri from the drug research company Elan drug Technologies Inc.

The article discusses research which was reported in the article "Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis" by A. Shirani et al. and found that the use of interferon beta in multiple sclerosis patients does not appear to slow the progress of the disease.

This section offers news briefs about clinical trials. The safety and efficacy of cytisine for stopping smoking was studied in a single-center, randomized, double-blind, placebo-controlled trial. The effect of the referral of primary care to a commercial weight loss treatment provider was conducted in a parallel group, non-blinded, randomized, controlled trial. The efficacy of teriflunomide for relapsing multiple sclerosis (MS) was evaluated in a randomized, controlled clinical trial.

About one in ten multiple sclerosis and epilepsy nurse specialist roles could be reduced in scope or axed altogether, health charities warn. [ABSTRACT FROM AUTHOR]

The article reports on the research by Thomas Kodadek of Scripps Florida and colleagues that could lead to the development of new treatments for multiple sclerosis (MS) and other conditions. It states that small molecules, which specifically bind to the autoreactive T cells surface of a mouse, were found by the team via a new screening process. Accordingly, research found that peptoid called AG12A, a kind of immune cell which attacks its host, helps to halt the MS development in mice.

The article reports on the 385 million U.S. dollar bid of Biogen Idec Inc. for Facet Biotech Corp. as its move to secure its business position in multiple sclerosis (MS) drugs development. It suggests that the move was prompted by the results of the antibody daclizumab in treating MS. It also mentions that on August 28, 2009, Facet announced development collaboration with Trubion Pharmaceuticals Inc. after it rejected the previous 400 million U.S. dollar proposal of Biogen on August 25, 2009.

The article discusses Extavia, a generic multiple sclerosis (MS) drug from Novartis AG. It mentions that the Food and Drug Administration (FDA) approved Extavia, Novartis' version of interferon beta-1b or Betaseron of Bayer AG. According to Bee Greener, drug analyst of Datamonitor, the approval of the drug is more on the entry of Novartis to neurology than to the sales potential due to the lack of experience of the company in MS field. Forecasts of Extavia sales in 2011 and 2013 are also cited.

The article reports that Biogen Idec Inc. and Acorda Therapeutics Inc. will jointly develop the latter's multiple sclerosis (MS) drug Fampridine-SR in markets outside the U.S. It notes that the move will help Biogen, which will provide up to $400 million in payments, expands its portfolio of sclerosis drugs and several small molecules in late-stage development. Accordingly, Fampridine-SR is designed to block potassium-ion channels to improve the insulation of frayed nerve fibers in the brain.

The article presents information on the results of a study by pharmacy benefits manager Prime Therapeutics on the impact of out-of-pocket costs on multiple sclerosis (MS) drug fill rates. The study discovered that MS patients with an out-of-pocket cost of 150 U.S. dollars or less have a decline-to-fill rate of 5.8%, while patients with greater than 150 U.S. dollars have a decline-to-fill rate of 27%. Lead study author Patrick Gleason emphasizes that patients who do not take their medications may suffer from serious medical and health complications.